Patents by Inventor Woodring E. Wright

Woodring E. Wright has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190029301
    Abstract: A method for treating a subject with multiple myeloma includes a step of identifying a patient having multiple myeloma. A fasting mimicking and enhancing diet is administered to the subject for a predetermined time period of at least 8 days. A diet package for implementing the method is also provided.
    Type: Application
    Filed: January 12, 2017
    Publication date: January 31, 2019
    Applicant: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: Valter D. LONGO, Woodring E. WRIGHT
  • Publication number: 20030190638
    Abstract: Method and compositions are provided for the determination of telomere length and telomerase activity, as well as the ability to increase or decrease telomerase activity in the treatment of proliferative diseases. Particularly, primers are elongated under conditions which minimize interference from other genomic sequences, so as to obtain accurate determinations of telomeric length or telomerase activity. In addition, compositions are provided for intracellular inhibition of telomerase activity and means are shown for slowing or reversing the loss of telomeric repeats in aging cells.
    Type: Application
    Filed: August 29, 2002
    Publication date: October 9, 2003
    Applicant: Board of Regents, The University of Texas System
    Inventors: Michael D. West, Calvin B. Harley, Scott L. Weinrich, Catherine M. Strahl, Michael J. McEachern, Jerry Shay, Woodring E. Wright, Elizabeth H. Blackburn, Nam Woo Kim, Homayoun Vaziri
  • Patent number: 6551774
    Abstract: Method and compositions are provided for the determination of telomere length and telomerase activity, as well as the ability to increase or decrease telomerase activity in the treatment of proliferative diseases. Particularly, primers are elongated under conditions which minimize interference from other genomic sequences, so as to obtain accurate determinations of telomeric length or telomerase activity. In addition, compositions are provided for intracellular inhibition of telomerase activity and means are shown for slowing or reversing the loss of telomeric repeats in aging cells.
    Type: Grant
    Filed: August 20, 1999
    Date of Patent: April 22, 2003
    Assignees: Board of Regents, The University of Texas System, The Regents of the University of California, Geron Corporation
    Inventors: Michael D. West, Calvin B. Harley, Scott L. Weinrich, Catherine M. Strahl, Michael J. McEachern, Jerry Shay, Woodring E. Wright, Elizabeth H. Blackburn, Nam Woo Kim, Homayoun Vaziri
  • Patent number: 6391554
    Abstract: Methods and kits are provided for diagnosis of specific cancerous conditions. The invention features a method for diagnosis of a condition in a patient associated with an elevated level of telomerase activity within a cell. The method involves determining the presence or amount of telomerase within the cells in the patient, e.g. by the use of the polymerase chain reaction. In one embodiment of the invention, the condition associated with elevated telomerase activity is chosen from prostate cancer, breast cancer, colon cancer, renal cancer, ovarian/cervical cancer, lung cancer, and leukemia. The invention allows cancer to be detected even in tissues and cells which are not positive by pathology.
    Type: Grant
    Filed: November 23, 1999
    Date of Patent: May 21, 2002
    Assignees: Geron Corporation and Board of Regents, The University of Texas Systems
    Inventors: Michael D. West, Jerry W. Shay, Woodring E. Wright, Nam Woo Kim, Calvin B. Harley, Scott L. Weinrich
  • Patent number: 6294650
    Abstract: The invention relates to peptide nucleic acids that inhibit telomerase activity in mammalian cells.
    Type: Grant
    Filed: July 8, 1999
    Date of Patent: September 25, 2001
    Assignee: The Board of Regents, University of Texas System
    Inventors: Jerry W. Shay, Woodring E. Wright, Mieczyslaw A. Piatyszek, David R. Corey, James C. Norton
  • Patent number: 6210915
    Abstract: A method of extracting telomerase from a cell sample having telomerase is provided which includes the step of contacting a cell sample with a buffer having (i) a non-ionic detergent at a concentration of not more than 5% (v/v) and (ii) an ionic detergent at a concentration of not more than 1 mM, to form a cell lysate. The method provides efficient extraction of telomerase that can be assayed for diagnostic and prognostic purposes.
    Type: Grant
    Filed: December 23, 1998
    Date of Patent: April 3, 2001
    Assignee: University of Texas Systems
    Inventors: Jerry W. Shay, Woodring E. Wright, James C. Norton, Jr.
  • Patent number: 6046307
    Abstract: The invention relates to peptide nucleic acids that inhibit telomerase activity in mammalian cells.
    Type: Grant
    Filed: April 9, 1997
    Date of Patent: April 4, 2000
    Assignee: The University of Texas System
    Inventors: Jerry W. Shay, Woodring E. Wright, Mieczyslaw A. Piatyszek, David R. Corey, James C. Norton
  • Patent number: 6015710
    Abstract: The invention relates to peptide nucleic acids that modulate telomerase activity in mammalian cells.
    Type: Grant
    Filed: April 9, 1996
    Date of Patent: January 18, 2000
    Assignee: The University of Texas System
    Inventors: Jerry W. Shay, Woodring E. Wright, Mieczyslaw A. Piatyszek, David R. Corey, James C. Norton
  • Patent number: 6007989
    Abstract: Method and compositions are provided for the determination of telomere length and telomerase activity, as well as the ability to increase or decrease telomerase activity in the treatment of proliferative diseases. Particularly, primers are elongated under conditions which minimize interference from other genomic sequences, so as to obtain accurate determinations of telomeric length or telomerase activity. In addition, compositions are provided for intracellular inhibition of telomerase activity and means are shown for slowing or reversing the loss of telomeric repeats in aging cells.
    Type: Grant
    Filed: March 14, 1997
    Date of Patent: December 28, 1999
    Assignees: Board of Regents, The University of Texas System, The Regents of the University of California, Geron Corporation
    Inventors: Michael D. West, Calvin B. Harley, Scott L. Weinrich, Catherine M. Strahl, Michael J. McEachern, Jerry Shay, Woodring E. Wright, Elizabeth H. Blackburn, Nam Woo Kim, Homayoun Vaziri
  • Patent number: 5989807
    Abstract: Methods and kits are provided for diagnosis of specific cancerous conditions. The invention features a method for diagnosis of a condition in a patient associated with an elevated level of telomerase activity within a cell. The method involves determining the presence or amount of telomerase within the cells in the patient, e.g. by the use of the polymerase chain reaction. In one embodiment of the invention, the condition associated with elevated telomerase activity is chosen from prostate cancer, breast cancer, colon cancer, renal cancer, ovarian/cervical cancer, lung cancer, and leukemia. The invention allows cancer to be detected even in tissues and cells which are not positive by pathology.
    Type: Grant
    Filed: June 7, 1994
    Date of Patent: November 23, 1999
    Assignees: Geron Corporation & Board of Regents, The University of Texas System
    Inventors: Michael D. West, Jerry Shay, Woodring E. Wright, Nam Woo Kim, Calvin B. Harley, Scott L. Weinrich
  • Patent number: 5830644
    Abstract: Method and compositions are provided for the determination of telomere length and telomerase activity, as well as the ability to increase or decrease telomerase activity in the treatment of proliferative diseases. Particularly, primers are elongated under conditions which minimize interference from other genomic sequences, so as to obtain accurate determinations of telomeric length or telomerase activity. In addition, compositions are provided for intracellular inhibition of telomerase activity and means are shown for slowing or reversing the loss of telomeric repeats in aging cells.
    Type: Grant
    Filed: November 12, 1993
    Date of Patent: November 3, 1998
    Assignees: Geron Corporation, Board of Regents, The University of Texas System
    Inventors: Michael D. West, Jerry Shay, Woodring E. Wright
  • Patent number: 5693474
    Abstract: A method for predicting tumor progression and prognosing cancer comprises: (a) collecting a sample suspected of containing cancer cells; (b) analyzing the sample for telomerase activity; (c) correlating the activity with a standard level of telomerase activity; and (d) correlating a high telomerase activity with an indication of unfavorable prognosis and a low telomerase activity with a favorable prognosis.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 2, 1997
    Assignee: Board of Regents, University of Texas System
    Inventors: Jerry Shay, Michael David West, Woodring E. Wright
  • Patent number: 5686306
    Abstract: Method and compositions for increasing telomere length in normal cells can be used to increase the proliferative capacity of cells and to delay the onset of cellular senescence.
    Type: Grant
    Filed: November 10, 1994
    Date of Patent: November 11, 1997
    Assignee: Board of Regents, The University of Texas System
    Inventors: Michael D. West, Jerry Shay, Woodring E. Wright
  • Patent number: 5648215
    Abstract: The presence of telomerase activity in a human somatic tissue or cell sample is positively correlated with the presence of cancer and can be used to diagnose the course of disease progression in a patient.
    Type: Grant
    Filed: September 28, 1994
    Date of Patent: July 15, 1997
    Assignee: Board of Regents, The University of Texas System
    Inventors: Michael D. West, Jerry Shay, Woodring E. Wright
  • Patent number: 5645986
    Abstract: Method and compositions are provided for the determination of telomere length and telomerase activity, as well as the ability to increase or decrease telomerase activity in the treatment of proliferative diseases. Particularly, primers are elongated under conditions which minimize interference from other genomic sequences, so as to obtain accurate determinations of telomeric length or telomerase activity. In addition, compositions are provided for intracellular inhibition of telomerase activity and means are shown for slowing or reversing the loss of telomeric repeats in aging cells.
    Type: Grant
    Filed: November 12, 1993
    Date of Patent: July 8, 1997
    Assignees: Board of Reagents, The University of Texas System, The Reagents of the University of California, Geron Corporation
    Inventors: Michael D. West, Calvin B. Harley, Catherine M. Strahl, Michael J. McEachern, Jerry Shay, Woodring E. Wright, Elizabeth H. Blackburn, Homayoun Vaziri
  • Patent number: 5639613
    Abstract: A method for predicting tumor progression and prognosing cancer comprises: (a) collecting a sample suspected of containing cancer cells; (b) analyzing the sample for telomerase activity; (c) correlating the activity with a standard level of telomerase activity; and (d) correlating a high telomerase activity with an indication of unfavorable prognosis and a low telomerase activity with a favorable prognosis.
    Type: Grant
    Filed: April 18, 1995
    Date of Patent: June 17, 1997
    Assignee: Board of Regents, University of Texas System
    Inventors: Jerry Shay, Michael David West, Woodring E. Wright
  • Patent number: 4659663
    Abstract: A method for isolating the fusion product of two cell populations is disclosed. The method involves the introduction of a specific antitoxin into cells of one population while introducing a second specific antitoxin into cells of the second population. After fusing cells of the first population with those of the second population, the fusion product may be selectively isolated on a medium containing an appropriate amount of both first and second toxins. For some applications, it may be appropriate to introduce an antitoxin into only one of the cell populations and isolate the fusion product on a media containing only one toxin.
    Type: Grant
    Filed: October 1, 1984
    Date of Patent: April 21, 1987
    Assignee: Board of Regents, University of Texas System
    Inventor: Woodring E. Wright